Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Intestinal2466 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A05128 | 33363046 | Front Cell Infect Microbiol | E. coli NF73-1 Isolated From NASH Patients Aggravates NAFLD in Mice by Translocating Into the Liver and Stimulating M1 Polarization. | 2020 | Details |
| A05134 | 33360580 | Environ Pollut | Exposure to nitenpyram during pregnancy causes colonic mucosal damage and non-alcoholic steatohepatitis in mouse offspring: The role of gut microbiota. | 2020 | Details |
| A05167 | 33347986 | Free Radic Biol Med | STING-dependent induction of lipid peroxidation mediates intestinal ischemia-reperfusion injury. | 2020 | Details |
| A05172 | 33346905 | Protein Cell | The role of the gut microbiome and its metabolites in metabolic diseases. | 2020 | Details |
| A05177 | 33346069 | Mol Metab | Metabolic drivers of non-alcoholic fatty liver disease. | 2020 | Details |
| A05185 | 33343508 | Front Endocrinol (Lausanne) | ChREBP-Mediated Regulation of Lipid Metabolism: Involvement of the Gut Microbiota, Liver, and Adipose Tissue. | 2020 | Details |
| A05223 | 33333240 | Respir Physiol Neurobiol | Functional foods from the tropics to relieve chronic normobaric hypoxia. | 2020 | Details |
| A05227 | 33331485 | Arq Gastroenterol | GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN GASTROINTESTINAL AND LIVER DISEASES: PROCEEDINGS OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN NUCLEUS FOR THE STUDY OF HELICOBACTER PYLORI AND MICROBIOTA (NBEHPM), AND BRAZILIAN FEDERATION OF GASTROENTEROLOGY (FBG). | 2021 | Details |
| A05228 | 33331479 | Arq Gastroenterol | PERIPHERAL BLOOD ENDOTOXIN LEVELS ARE NOT ASSOCIATED WITH SMALL INTESTINAL BACTERIAL OVERGROWTH IN NONALCOHOLIC FATTY LIVER DISEASE WITHOUT CIRRHOSIS. | 2021 | Details |
| A05239 | 33327816 | J Int Med Res | Using intestinal flora to distinguish non-alcoholic steatohepatitis from non-alcoholic fatty liver. | 2020 | Details |
| A05243 | 33327227 | Medicine (Baltimore) | Study on the new strategy and key techniques for accurate prevention and treatment of nonalcoholic steatohepatitis based on intestinal target bacteria. | 2020 | Details |
| A05249 | 33324348 | Front Endocrinol (Lausanne) | Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides. | 2020 | Details |
| A05253 | 33322323 | Animals (Basel) | GC-TOF-MS-Based Metabolomics Analyses of Liver and Intestinal Contents in the Overfed vs. Normally-Fed Geese. | 2020 | Details |
| A05269 | 33318628 | Cell Mol Immunol | Gut microbiome, liver immunology, and liver diseases. | 2020 | Details |
| A05273 | 33317254 | Clin Mol Hepatol | Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. | 2020 | Details |
| A05284 | 33312845 | Curr Treat Options Pediatr | When the beverage is sweet, how does the liver feel? | 2019 | Details |
| A05293 | 33310185 | Biochem Biophys Res Commun | Impaired CCR9/CCL25 signalling induced by inefficient dendritic cells contributes to intestinal immune imbalance in nonalcoholic steatohepatitis. | 2020 | Details |
| A05297 | 33309563 | Clin Res Hepatol Gastroenterol | Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. | 2020 | Details |
| A05341 | 33296678 | Cell Metab | Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A05347 | 33291863 | Clin Mol Hepatol | The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. | 2020 | Details |
| A05364 | 33281770 | Front Microbiol | Novel Odoribacter splanchnicus Strain and Its Outer Membrane Vesicles Exert Immunoregulatory Effects in vitro. | 2020 | Details |
| A05414 | 33268508 | Sci Transl Med | Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. | 2020 | Details |
| A05450 | 33252713 | Protein Cell | Targeting the alternative bile acid synthetic pathway for metabolic diseases. | 2020 | Details |
| A05461 | 33248976 | Arab J Gastroenterol | Association of obesity and non-alcoholic fatty liver disease with the fecal calprotectin level in children. | 2020 | Details |
| A05473 | 33246225 | Biomed Pharmacother | Akkermansia muciniphila: A potential novel mechanism of nuciferine to improve hyperlipidemia. | 2020 | Details |
| A05479 | 33242590 | Biochim Biophys Acta Mol Basis Dis | Regulation of autophagy by bile acids and in cholestasis - CholestoPHAGY or CholeSTOPagy. | 2020 | Details |
| A05489 | 33235221 | Nat Commun | Intestinal FGF15/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A. | 2020 | Details |
| A05514 | 33220492 | Mol Metab | Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. | 2020 | Details |
| A05535 | 33216087 | Food Funct | Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice. | 2020 | Details |
| A05562 | 33205261 | Curr Gastroenterol Rep | Endobariatrics and Metabolic Endoscopy: Can We Solve the Obesity Epidemic with Our Scope? | 2020 | Details |
| A05568 | 33204402 | Oxid Med Cell Longev | Chicoric Acid Ameliorates Nonalcoholic Fatty Liver Disease via the AMPK/Nrf2/NFκB Signaling Pathway and Restores Gut Microbiota in High-Fat-Diet-Fed Mice. | 2020 | Details |
| A05579 | 33201570 | J Gastroenterol Hepatol | The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development. | 2020 | Details |
| A05582 | 33200017 | World J Hepatol | PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. | 2020 | Details |
| A05603 | 33193105 | Front Endocrinol (Lausanne) | Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH. | 2020 | Details |
| A05623 | 33185911 | Hepatology | Neutral Ceramidase Mediates Nonalcoholic Steatohepatitis by Regulating Monounsaturated Fatty Acids and Gut IgA+ B Cells. | 2021 | Details |
| A05627 | 33184021 | Nanomedicine | Formulation and intestinal absorption of naringenin loaded nanostructured lipid carrier and its inhibitory effects on nonalcoholic fatty liver disease. | 2020 | Details |
| A05628 | 33183606 | Carbohydr Polym | Friend or foe? The roles of inulin-type fructans. | 2020 | Details |
| A05630 | 33182700 | Nutrients | Fructose-Induced Intestinal Microbiota Shift Following Two Types of Short-Term High-Fructose Dietary Phases. | 2020 | Details |
| A05635 | 33180143 | Eur J Nutr | A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier. | 2020 | Details |
| A05642 | 33177790 | World J Gastroenterol | Role of gut microbiota via the gut-liver-brain axis in digestive diseases. | 2020 | Details |
| A05643 | 33177712 | Nature | A reference map of potential determinants for the human serum metabolome. | 2020 | Details |
| A05654 | 33171747 | Int J Mol Sci | The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage. | 2020 | Details |
| A05663 | 33168782 | Aging (Albany NY) | Human mesenchymal stem cells treatment improved hepatic lesions and reversed gut microbiome disorder in non-alcoholic steatohepatitis. | 2020 | Details |
| A05665 | 33167521 | Int J Mol Sci | Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression. | 2020 | Details |
| A05698 | 33151407 | J Gastroenterol | The gut mycobiome: a novel player in chronic liver diseases. | 2020 | Details |
| A05757 | 33131411 | Gut Microbes | Lactobacillus lactis CKDB001 ameliorate progression of nonalcoholic fatty liver disease through of gut microbiome: addendum. | 2020 | Details |
| A05764 | 33127939 | Sci Rep | Supplementation of branched-chain amino acids decreases fat accumulation in the liver through intestinal microbiota-mediated production of acetic acid. | 2020 | Details |
| A05767 | 33126575 | Nutrients | Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update. | 2020 | Details |
| A05781 | 33119943 | Br J Pharmacol | Intestinal absorption and hepatic elimination of drugs in high-fat high-cholesterol diet-induced non-alcoholic steatohepatitis rats: exemplified by simvastatin. | 2020 | Details |
| A05786 | 33117316 | Front Microbiol | Microbial Metabolites: Critical Regulators in NAFLD. | 2020 | Details |
| A05792 | 33115780 | Cancer Prev Res (Phila) | Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer. | 2020 | Details |
| A05803 | 33114130 | Nutrients | Bilberry Anthocyanins Ameliorate NAFLD by Improving Dyslipidemia and Gut Microbiome Dysbiosis. | 2020 | Details |
| A05829 | 33105554 | Nutrients | Prebiotic Xylo-Oligosaccharides Ameliorate High-Fat-Diet-Induced Hepatic Steatosis in Rats. | 2020 | Details |
| A05853 | 33101207 | Front Endocrinol (Lausanne) | Chinese Medicinal Herbs Targeting the Gut-Liver Axis and Adipose Tissue-Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science. | 2020 | Details |
| A05866 | 33096076 | Metabolism | Pharmacological activation of REV-ERBα improves nonalcoholic steatohepatitis by regulating intestinal permeability. | 2020 | Details |
| A05869 | 33095225 | Food Funct | Green tea polyphenol epigallocatechin-3-gallate alleviates nonalcoholic fatty liver disease and ameliorates intestinal immunity in mice fed a high-fat diet. | 2020 | Details |
| A05901 | 33081177 | Nutrients | Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms. | 2020 | Details |
| A05907 | 33079450 | Mol Nutr Food Res | The Beneficial Effects of Apical Sodium-Dependent Bile Acid Transporter Inactivation Depend on Dietary Fat Composition. | 2020 | Details |
| A05981 | 33053631 | Nutrients | Microbiota, Fiber, and NAFLD: Is There Any Connection? | 2020 | Details |
| A05985 | 33050862 | Curr Pharm Biotechnol | Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review. | 2022 | Details |
| A05991 | 33049668 | Front Biosci (Landmark Ed) | Current treatment paradigms and emerging therapies for NAFLD/NASH. | 2021 | Details |
| A06011 | 33038432 | J Hepatol | Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. | 2020 | Details |
| A06016 | 33037768 | Liver Int | Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis. | 2020 | Details |
| A06020 | 33037249 | Sci Rep | Pathophysiology of high fat diet induced obesity: impact of probiotic banana juice on obesity associated complications and hepatosteatosis. | 2020 | Details |
| A06022 | 33036939 | Surg Obes Relat Dis | Recent advances in the mechanisms underlying the beneficial effects of bariatric and metabolic surgery. | 2020 | Details |
| A06030 | 33034193 | J Agric Food Chem | High-Fat Proteins Drive Dynamic Changes in Gut Microbiota, Hepatic Metabolome, and Endotoxemia-TLR-4-NFκB-Mediated Inflammation in Mice. | 2020 | Details |
| A06038 | 33032263 | J Endocrinol | Lactobacillus pentosus strain S-PT84 improves steatohepatitis by maintaining gut permeability. | 2020 | Details |
| A06056 | 33026380 | Food Funct | Gut inflammation exacerbates hepatic injury in C57BL/6J mice via gut-vascular barrier dysfunction with high-fat-incorporated meat protein diets. | 2020 | Details |
| A06060 | 33024915 | Hepatol Commun | Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice. | 2020 | Details |
| A06069 | 33020474 | Nat Commun | Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. | 2020 | Details |
| A06112 | 33002297 | Mol Nutr Food Res | Huangjinya Black Tea Alleviates Obesity and Insulin Resistance via Modulating Fecal Metabolome in High-Fat Diet-Fed Mice. | 2020 | Details |
| A06116 | 32999906 | GE Port J Gastroenterol | Gastrointestinal Microbiome - What We Need to Know in Clinical Practice. | 2020 | Details |
| A06122 | 32998095 | Diabetes Metab Syndr | Pathophysiological mechanisms underlying MAFLD. | 2020 | Details |
| A06139 | 32992082 | Phytomedicine | Integrated omics analysis unraveled the microbiome-mediated effects of Yijin-Tang on hepatosteatosis and insulin resistance in obese mouse. | 2020 | Details |
| A06147 | 32987188 | Mol Metab | Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. | 2020 | Details |
| A06156 | 32984364 | Front Med (Lausanne) | Disturbances in Cholesterol Homeostasis and Non-alcoholic Fatty Liver Diseases. | 2020 | Details |
| A06160 | 32982365 | Clin Exp Gastroenterol | Gut Dysbiosis and Increased Intestinal Permeability Drive microRNAs, NLRP-3 Inflammasome and Liver Fibrosis in a Nutritional Model of Non-Alcoholic Steatohepatitis in Adult Male Sprague Dawley Rats. | 2020 | Details |
| A06161 | 32982113 | World J Gastroenterol | Acupuncture improved lipid metabolism by regulating intestinal absorption in mice. | 2020 | Details |
| A06213 | 32965553 | Wien Klin Wochenschr | Association between psoriasis, psoriatic arthritis and gastrointestinal disease : An exploratory nationwide inpatient sample analysis. | 2020 | Details |
| A06232 | 32961235 | Life Sci | Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice. | 2020 | Details |
| A06273 | 32945305 | Food Funct | Lactobacillus fermentum CQPC06 in naturally fermented pickles prevents non-alcoholic fatty liver disease by stabilizing the gut-liver axis in mice. | 2020 | Details |
| A06327 | 32927776 | Nutrients | New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. | 2020 | Details |
| A06328 | 32927075 | J Am Coll Surg | Preventive Effect of High-Dose Digestive Enzyme Management on Development of Nonalcoholic Fatty Liver Disease after Pancreaticoduodenectomy: A Randomized Controlled Clinical Trial. | 2020 | Details |
| A06395 | 32895402 | Sci Rep | Long-term effects of western diet consumption in male and female mice. | 2020 | Details |
| A06400 | 32892668 | Expert Rev Gastroenterol Hepatol | Non-alcoholic fatty liver disease: molecular and cellular interplays of the lipid metabolism in a steatotic liver. | 2020 | Details |
| A06435 | 32882426 | Clin Gastroenterol Hepatol | Exercise Training Reverses Gut Dysbiosis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis: A Proof of Concept Study. | 2020 | Details |
| A06446 | 32879216 | Biol Pharm Bull | A Lipid-Based Nanocarrier Containing Active Vitamin D3 Ameliorates NASH in Mice via Direct and Intestine-Mediated Effects on Liver Inflammation. | 2020 | Details |
| A06471 | 32867260 | Medicina (Kaunas) | Probiotics: Versatile Bioactive Components in Promoting Human Health. | 2020 | Details |
| A06474 | 32865911 | Crit Rev Oncog | Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression. | 2020 | Details |
| A06502 | 32850884 | Front Med (Lausanne) | Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. | 2020 | Details |
| A06516 | 32846589 | Food Res Int | Monascus purpureus-fermented common buckwheat protects against dyslipidemia and non-alcoholic fatty liver disease through the regulation of liver metabolome and intestinal microbiome. | 2020 | Details |
| A06517 | 32845887 | PLoS One | Association of worsening of nonalcoholic fatty liver disease with cardiometabolic function and intestinal bacterial overgrowth: A cross-sectional study. | 2020 | Details |
| A06528 | 32839596 | Nat Metab | Fructose stimulated de novo lipogenesis is promoted by inflammation. | 2020 | Details |
| A06547 | 32830817 | J Gastrointestin Liver Dis | Non-alcoholic Steatohepatitis: Comparison of Intestinal Microbiota between Different Metabolic Profiles. A Pilot Study. | 2020 | Details |
| A06558 | 32825440 | Int J Mol Sci | Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. | 2020 | Details |
| A06567 | 32823983 | J Clin Med | Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. | 2020 | Details |
| A06568 | 32823659 | Int J Mol Sci | Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. | 2020 | Details |
| A06574 | 32822324 | Orv Hetil | Fat rich diet-induced steatosis and changes in the gut–liver axis | 2020 | Details |
| A06581 | 32821071 | World J Gastroenterol | Helicobacter pylori infection: Beyond gastric manifestations. | 2020 | Details |
| A06590 | 32816619 | Gut Microbes | Modifying macronutrients is superior to microbiome transplantation in treating nonalcoholic fatty liver disease. | 2020 | Details |